05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:
|
|
- Rosemary Harrell
- 5 years ago
- Views:
Transcription
1 Organisation The English screening programme what is happening? Phil Quirke Lead Pathologist Bowel Cancer Screening PHE England Bowel Cancer Screening Pathology Committee Started 2006 with roll out 4 devolved countries 60M England 49M guiac FOBT but moving to FIT Bowelscope started 2013 once only at 55 rolling out Wales and Northern Ireland guiac FOBT Scotland guiac FOBT to FIT 20+5 Bowel cancer screening in the UK is: Organisation CHANGING THE SPECTRUM OF DISEASE AND ITS MANAGEMENT Increasing the incidence of colorectal cancer in the population Increasing early stage disease stage I from 11% to 29% Increasing pt1 cancers and local excisions 3 fold to 16.9% Increasing the number of surgically operable patients Reducing stage IV disease Improving endoscopy technique Improving pathology Improving outcomes Overarching Pathology committee with representation and input from Republic of Ireland (Kieran Sheehan) FIT Consistency of definitions and recommendations across Pathology new guidance and TNM8 update EQA across all countries Different levels of quality assurance across programme 1
2 England Uptake and positivity Prevalent first invitation uptake: 51.94% Gateshead Nottingham Rugby London Guildford Five Regional screening hubs Pathology committee responsible for quality Pathology guidance QA visits EQA rounds Expert panel January 2018 Screening round Uptake Positivity Prevalent 35.04% 2.19% Incident 85.69% 1.72% Total 56.61% 1.89% FOBT programme 2006 to May31 st 2018 Diagnostic tests Invitations Self referrals Kits sent Kits returned Definitive normals Definitive abnormals 39,450, ,753 41,865,295 24,494,071 21,817, ,145 2
3 Episode outcomes Bowelscope ,195 controls 57,237 flexisigmoidoscopy 40,674 underwent it Age 60 Incidence 23% (33%) drop Mortality 31% (43%) drop Left sided/rectal cancer 50% incidence drop Distal Proximal Control F/S Control F/S Lesions found 2006-May 2018 Long term effects at 17 years Polyp type Count % Tubular adenoma 354, % Tubulovillous adenoma 94, % Villous adenoma 5, % Serrated adenoma 4, % Mixed HP/adenoma 1, % Hyperplastic 121, % Sessile serrated lesion 4, % Traditional serrated adenoma % Mixed polyp % Sessile serrated lesion with dysplasia % Inflammatory polyp 7, % Other polyp 2, % Lymphoid % Lipoma % Not polyp 36, % Grand total 642, % Adenoma Histology Size Histology size Count % 1-9mm 358, % 10-19mm 77, % 20-29mm 17, % 30-39mm 4, % 40-49mm 1, % 50mm Plus 1, % Not Entered 1, % Grand Total 462, % 3
4 Bowelscope Bowelscope lesions found Importance of removal of lesions developing at 55 rather than 60 or later? Bowelscope uptake and workload What are the tribulations? Bowelscope 395,000 flexisigmoidoscopies and colonoscopies gfobt 450,000 Colonoscopies and flexisigmoidoscopies Over diagnosing pt1 cancer NS Serrated lesions - NS Endoscopy size is unreliable new guidance Incomplete excision does not mean residual disease We are over resecting pt1 cancers and losing patients from operative mortality Interval cancers 4
5 Double reporting Double reporting of all pt1 cancers is required to minimise overdiagnosis of adenocarcinoma. Both reporting pathologists should be BCSP registered and named on the pathology report. If there is any doubt about a diagnosis of cancer, then referral is required for a further opinion. It is recommended that a local opinion is sought first with a further regional opinion or opinion from the national Expert Board should the diagnosis still be in doubt. Main updates 2 Elaboration of standards applicable to pathologists reporting BCSP specimens (section 3.1). Expectations required of endoscopists submitting BCSP specimens for histology (section 3.4). Careful consideration of adenoma sizing, given importance relevant to stratification for colonoscopic surveillance (sections 2 and 5.2.2). Elaboration of descriptors and minimum diagnostic criteria for villousness, in an attempt to improve reproducibility (section 5.2.3). Main updates 1 Reporting to RCPath MDS 2017 TNM8 Reporting of stage pt1 CRC in line with recommendations to include depth and width of invasion (in mm) and separate assessment of lymphatic, neural and venous invasion (section 4.3). [2] Minimum interim standard to perform mismatch repair (MMR) immunohistochemistry in cases of stage pt1 CRC diagnosed in the BCSP setting which demonstrate poor differentiation or other features suggestive of MMR deficiency (section 4.5). NICE recommendation to perform mismatch repair (MMR) immunohistochemistry or microsatellite instability (MSI) testing in all cases of colorectal cancer diagnosed in the BCSP setting [4]. Main updates 3 Assessment of polypectomy margin distinguishing margin involvement by dysplasia from incomplete excision (section 5.2.5). Detailed discussion of epithelial misplacement within adenomas versus adenocarcinoma (section 5.2.6). Update in terminology to be applied to serrated lesions (section 5.2). Minimum criteria for diagnosing adenocarcinoma on endoscopic biopsy specimens (section 4.2). 5
6 Measurement of size Endoscopy size Inaccurate Increased follow up by 10% Terminal digit preference Measuring device Guidance Hierarchy On slide - graticule Cut up Nurse Endoscopy Margin distance There is, however, recent evidence to suggest that for pt1 tumours only tumour present at the true or estimated resection margin, or within the diathermy burn zone, should be considered for further treatment, which may be local re-excision if no other adverse pathology features are identified [34,35,53]. However, it is considered that more substantive evidence is required before a change is made and 1mm or less remains the indicator for incomplete excision until this is forthcoming. If tumour is close to the excision margin, multiple levels (at least three and preferably more) should be examined in the assessment of possible margin involvement, with adjunctive immunohistochemistry if required. Careful follow-up of the local excision site of carcinomas less than 1mm from the margin is recommended if the MDT decide not to undertake a further excision or resection. Margins guidance to NHSBCSP -more work needed Management pt1 Major resection Complications Mortality Surgical team Country Age Health Morbidity Quality of life Stoma Anterior resection syndrome Cost 16,000, stomas No resection/local excision Risk of recurrence and cancer death Currently select by High risk features Sub stage pt1 Lymphovascular invasion Poor differentiation Incomplete excision 10% metastases symptomatic pt1 patients Less in screening patients 6
7 pt1 Conclusions Hagitt/Kikuchi remain for now Ueno et al have proposed that the depth of invasion of tumour beyond the muscularis mucosae and width of the invasive tumour provide more objective measures of potential for lymph node metastasis [46]. Both of these quantitative measurements should also be recorded, in millimetres, in line with the recommendation of the Royal College of Pathologists (UK) dataset [2]. Depth (or thickness) of invasive tumour should be measured from the muscularis mucosae where it is intact and identifiable. If the muscularis mucosae is obscured or destroyed by tumour, tumour thickness should be measured from the surface of intact mucosa or ulcer [47]. Budding is not yet recommended needs studies with the new ITBCC guidance Bowel cancer screening is working in the UK Need to increase the colonoscopy capacity to maximise its benefits Still outstanding issues that need resolution The outstanding issues Thanks to: Increasing screening uptake and increased sensitivity of detection Political Increasing FIT sensitivity vs continuing bowelscope Biomedical scientist reporting Diagnostic pt1 indications for resection Positive margins Role of local treatments Role of MRI in follow up of high risk pt1 s low risk T2 s Biology of serrated lesions Pathology Committee NHSBCSP and Claire Nickerson Eva Morris Julieta Patnick 7
8 Cancer staging per tumour Cancer Stage Tumour Count No cancer detected 1,094 Stage 1 7,376 Stage 2a 3,973 Stage 2b 332 Stage 3a 1,450 Stage 3b 3,642 Stage 3c 1,330 Stage 4 2,063 Incomplete 7,149 Cannot be assessed 3,914 Grand Total 32,323 8
Pathology in Slovenian CRC screening programme:
Pathology in Slovenian CRC screening programme: Findings, organisation and quality assurance Snježana Frković Grazio University Medical Center Ljubljana, Slovenia Slovenia s population: 2 million Incidence
More informationPathology in Slovenian CRC screening programme: Organisation and quality assurance. Snježana Frković Grazio and Matej Bračko
Pathology in Slovenian CRC screening programme: Organisation and quality assurance Snježana Frković Grazio and Matej Bračko June 2009 to December 2013 (first three rounds) 33 969 colonoscopies were performed
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationPolypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma
Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth
More informationmalignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen
Plan Incidental finding of a malignant polyp 1. What is a polyp malignant? 2. Role of the pathologist and the endoscopist 3. Quantitative and qualitative risk assessment 4. How to decide what to do? Hubert
More informationQA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013
QA Processes Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013 Standards QA visits Dashboards BCSP standards Standards for Organisation Service delivery Reporting Data quality Audit and
More informationSCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE
SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal
More informationNeoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012
Neoplastic Colon Polyps Joyce Au SUNY Downstate Grand Rounds, October 18, 2012 CASE 55M with Hepatitis C, COPD (FEV1=45%), s/p vasectomy, knee surgery Meds: albuterol, flunisolide, mometasone, tiotropium
More informationCOLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.
The West London Medical Journal 2009 Vol No 1 pp 23-31 COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. Competing interests: None declared ABSTRACT Sarah
More informationManagement of pt1 polyps. Maria Pellise
Management of pt1 polyps Maria Pellise Early colorectal cancer Malignant polyp Screening programmes SM Invasive adenocar cinoma Advances in diagnostic & therapeutic endoscopy pt1 polyps 0.75 5.6% of large-bowel
More information05/07/2018. What colorectal cancer screening is all about. Not so simple pathology: issues from the screening programme
Not so simple pathology: issues from the screening programme Professor Neil A Shepherd Gloucester & Cheltenham, UK What colorectal cancer screening is all about. detecting early stage cancer D 25% A 8%
More informationAdenoma and Malignant Colorectal Polyp: Pathological Considerations and Clinical Applications
Adenoma and Malignant Colorectal Polyp: Pathological Considerations and Clinical Applications Authors: *Emil Salmo, 1 Najib Haboubi 2 1. Department of Histopathology, The Pennine Acute Hospitals NHS Trust,
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationResource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies
More informationEmerging Interventions in Endoscopy. Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital
Emerging Interventions in Endoscopy Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital Colon Cancer Colon cancer is common. 1 in 20 people in the UK will develop the disease 19 000
More informationWhen is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool
When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs
More informationPATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS
PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS Produced by: Address: Yorkshire Cancer Network Pathology Group Arthington House, Cookridge Hospital, Hospital
More informationNHS Bowel Cancer Screening Programme Guidance on reporting lesions. Public Health England leads the NHS Screening Programmes
NHS Bowel Cancer Screening Programme Guidance on reporting lesions Public Health England leads the NHS Screening Programmes About Public Health England Public Health England (PHE) exists to protect and
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More informationEuropean guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition
SE116 European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Quality assurance in pathology in colorectal cancer screening and diagnosis Co-Funded by the
More informationCOLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE
COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE Guideline Authors: Todd S. Crocenzi, M.D.; Mark Whiteford, M.D.; Matthew Solhjem, M.D.; Carlo Bifulco, M.D.; Melissa Li, M.D.; Christopher Cai, M.D.;
More informationData briefing: Reflex testing for Lynch syndrome in people diagnosed with bowel cancer under the age of 50
Data briefing: Reflex testing for Lynch syndrome in people diagnosed with bowel cancer under the age of 50 Introduction Lynch syndrome is an inherited condition that predisposes individuals to bowel and
More informationADENOMA SURVEILLANCE BCSP Guidance Note No 1 Version 1 September 2009
ADENOMA SURVEILLANCE BCSP Guidance Note No 1 Version 1 September 2009 Published by: NHS Cancer Screening Programmes Fulwood House Old Fulwood Road Sheffield S10 3TH Tel: 0114 271 1060 Fax: 0114 271 1089
More informationNorthern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013
Northern Ireland Bowel Cancer Screening Programme Pathways These changes will be version controlled, led by the Quality Assurance Director for the Programme. Any updated versions will be circulated and
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More informationBowel Cancer Screening
Bowel Cancer Screening Dr John Hancock FRCP Consultant Gastroenterologist University Hospital of North Tees Outline Background Current bowel cancer screening programme Tees Screening Centre Future Flexi
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationScreening for Colorectal Cancer: Se0ng it up and making it work. Julie8a Patnick 4 December 2014
Screening for Colorectal Cancer: Se0ng it up and making it work Julie8a Patnick 4 December 2014 Evaluation of the UK Colorectal Cancer Screening Pilot Two sites, population ~ 1m Coventry & Warwickshire
More informationColon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4
Colon Cancer Screening Layth Al-Jashaami, MD GI Fellow, PGY 4 -Colorectal cancer (CRC) is a common and lethal cancer. -It has the highest incidence among GI cancers in the US, estimated to be newly diagnosed
More informationBowel Screening Wales E-Bulletin October 2010
Bowel Screening Wales E-Bulletin October 2010 News I am delighted to have returned to work after 5 months sick leave and would like to thank everyone for all their hard work and kind wishes while I was
More informationQuality assurance in pathology in colorectal cancer screening and diagnosis European recommendations
Virchows Arch (2011) 458:1 19 DOI 10.1007/s00428-010-0977-6 REVIEW AND PERSPECTIVE Quality assurance in pathology in colorectal cancer screening and diagnosis European recommendations Phil Quirke Mauro
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationBowel screening cancer prevention
Bowel screening cancer prevention David S Morrison Consultant in Public Health Medicine 22 nd September 2016 Bowel cancer incidence since 1979 http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-by-cancertype/bowel-cancer/incidence#heading-two
More informationcolorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018
colorectal cancer Adenocarcinoma of the colon and rectum is the third most common site of new cancer cases and deaths in men (following prostate and lung or bronchus cancer) and women (following breast
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationColorectal cancer screening in England
Colorectal cancer screening in England critical analysis Prof Stephen P. Halloran Participation Rate 57% All Screens (1.9% +ve) 52% Prevalent 1 st Screen (age 60 years) 36% Prevalent Screen (2.2% +ve)
More informationLarge Colorectal Adenomas An Approach to Pathologic Evaluation
Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,
More informationExpert panel observations
Expert panel observations Professor Neil A Shepherd Gloucester and Cheltenham, UK Gloucestershire Cellular Pathology Laboratory Three big issues in BCSP pathology serrated pathology & what do we do about
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationA916: rectum: adenocarcinoma
General facts of colorectal cancer The colon has cecum, ascending, transverse, descending and sigmoid colon sections. Cancer can start in any of the r sections or in the rectum. The wall of each of these
More informationThe Kamal Ishak Lecture. The pathology of bowel cancer screening
The Kamal Ishak Lecture The pathology of bowel cancer screening Professor Neil A Shepherd Gloucester & Cheltenham, UK 27 th IAP-AD Congress 2 nd Emirates Surgical Pathology Conference Dubai, 26 November
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationUK Bowel Cancer screening Dr Voi Shim Wong BsC MD FRCP. Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals
UK Bowel Cancer screening 2017 Dr Voi Shim Wong BsC MD FRCP Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals Bowel Cancer Contents UK Bowel Cancer Screening Programme
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy Authors: Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments 1.1 Cancer reporting: Biopsies
More informationDouglas K. Rex, MD Indiana University Hospital Indianapolis, IN
Serrated Adenomas: What do they mean and what to do about them? Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN Colorectal Cancer Molecular Basis Pathway Frequency Genes MSI Precursor Speed
More informationMalignant colorectal polyps: venous invasion and
774 Gut, 1991,32, 774-778 Malignant colorectal polyps: venous invasion and successful treatment by endoscopic polypectomy Department of Pathology J M Geraghty Endoscopy Unit C B Williams and ICRF Colorectal
More informationPseudoinvasion and how to deal with it
Pseudoinvasion and how to deal with it Professor Neil A Shepherd Gloucester & Cheltenham, UK European Society of Pathology Bilboa, 12 June 2018 Enterprise Interest None Pseudoinvasion and how to deal with
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationThe malignant colorectal polyp
The malignant colorectal polyp Dr Ian Brown Envoi Pathology Envoi data reproduced from J Clin Path 2015 article Definition Adenocarcinoma found in an endoscopically resected polypoidal tumour Submucosal
More informationYorkshire Cancer Research Yorkshire Bowel Cancer initiative
Yorkshire Cancer Research Yorkshire Bowel Cancer initiative Phil Quirke, Eva Morris, Paul Finan, Nick West, Penny Wright, David Sebag- Montefiore, Matt Seymour University of Leeds What s the problem? %
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationImaging Evaluation of Polyps. CT Colonography: Sessile Adenoma. Polyps, DALMs & Megacolon Objectives
Polyps, DALMs & Megacolon: Pathology and Imaging of the Colon and Rectum Angela D. Levy and Leslie H. Sobin Washington, DC Drs. Levy and Sobin have indicated that they have no relationships which, in the
More informationLarge polyps: EMR, ESD, TEM and segmental resection. Terry Phang 2017 SON fall update
Large polyps: EMR, ESD, TEM and segmental resection Terry Phang 2017 SON fall update Key Points: Large polyps No RCT re: Recurrence, complications Piecemeal vs en bloc: EMR vs ESD Partial vs full-thickness:
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationADENOMAS WITH ADENOCARCINOMA: A STUDY EVALUATING THE RISK OF RESIDUAL CANCER AND LYMPH NODE METASTASIS
253SJS102210.1177/1457496913482253S. E. Steigen, et al.adenomas with adenocarcinomas and risk factors Scandinavian Journal of Surgery 102: 90 95, 2013 ADENOMAS WITH ADENOCARCINOMA: A STUDY EVALUATING THE
More informationNorthern Ireland Bowel Cancer Screening Programme
Northern Ireland Bowel Cancer Screening Programme Inaugural Report April 2010 March 2013 Published: 30 October 2014 (amended: 3 December 2014) 2 P a g e Contents Contents... 3 Foreword... 7 1 Introduction...
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationNATIONAL SCREENING COMMITTEE
Optimising Bowel Cancer Screening Phase 1: Optimising the cost effectiveness of repeated FIT screening and screening strategies combining bowel scope and FIT screening Sophie Whyte, Chloe Thomas, Ben Kearns,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators
More informationProf Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT
Prof Stephen P. Halloran Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT World Top 20 Cancers Men Incidence & Mortality (2012) Women World Colorectal Cancer 3 rd commonest cancer 4
More informationBe it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE
Be it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE DEBATE Presenters PRESENTATION MODERATOR Dr. Praveen Bansal -MD, CCFP FCFP Regional Primary Care Lead, Integrated Cancer Screening,
More informationRazvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationSurveying the Colon; Polyps and Advances in Polypectomy
Surveying the Colon; Polyps and Advances in Polypectomy Educational Objectives Identify classifications of polyps Describe several types of polyps Verbalize rationale for polypectomy Identify risk factors
More informationPost-polypectomy follow-up after. removal of colorectal neoplasia
Post-polypectomy follow-up after removal of colorectal neoplasia Post-polypectomy endoscopic surveillance For each type of polyp BENEFIT 1. What is the risk of CRC/Adv. Neo. (AN) w/out surveillance?
More informationExperience and challenges of implementing optical diagnosis into clinical practice UK and European Perspective
Experience and challenges of implementing optical diagnosis into clinical practice UK and European Perspective WEO Image Enhanced Endoscopy San Diego, USA Dr James East Consultant Gastroenterologist Honorary
More informationHyperplastische Polyps Innocent bystanders?
Hyperplastische Polyps Innocent bystanders?? K. Geboes P th l i h O tl dk d Pathologische Ontleedkunde, KULeuven Content Historical Classification Relation Hyperplastic polyps carcinoma The concept cept
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationCarol A. Burke, MD, FACG
Updated Guidelines for CRC C Screening and Surveillance Carol A. Burke MD, FACG, FASGE, FACP Cleveland Clinic, Cleveland, OH Gastroenterology t 2012;143:844 143 Gut 2010;59:666 1 Caveat for all Recommendations
More informationEARLY DETECTION OF COLORECTAL CANCER. Epidemiology of CRC
Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER Epidemiology of CRC Colorectal cancer (CRC) is a common and lethal disease Environmental
More informationUpdate on Colonic Serrated (and Conventional) Adenomatous Polyps
Update on Colonic Serrated (and Conventional) Adenomatous Polyps Maui, HI 2018 Robert D. Odze, MD, FRCPC Chief, Division of GI Pathology Professor of Pathology Brigham and Women s Hospital Harvard Medical
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationAn Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018
An Update on the Bowel Cancer Screening Programme Natasha Djedovic, London Hub Director 17 th September 2018 NHS Bowel Cancer Screening Programme 2006: 60-69 yr old men & women offered guaiac Faecal Occult
More informationImplementing of Population-based FOBT Screening
Implementing of Population-based FOBT Screening gfobt to FIT Experience from England Prof Stephen P. Halloran Guaiac FOBt Haem 2H 2 O 2 = 2H 2 0 + O 2 Oxidised guaiaconic acid is blue Biennial Bowel Cancer
More informationWEO CRC SC Meeting. Barcelona, Spain October 23, 2015
WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,
More informationCHAPTER 7 Concluding remarks and implications for further research
CONCLUDING REMARKS AND IMPLICATIONS FOR FURTHER RESEARCH CHAPTER 7 Concluding remarks and implications for further research 111 CHAPTER 7 Molecular staging of large sessile rectal tumors In this thesis,
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Colon polyps Colorectal cancer Harrison s Principles of Internal Medicine 18 Ed. 2012 Colorectal cancer 70% Colorectal cancer CRC and colon
More informationColorectal cancer screening
26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant
More informationFormula One Study. Assessment criteria of pathological parameters. Ver.2. UK Japan Joint Study for Risk Factors of Lymph Node
APPENDIX 01: Assessment criteria Formula One Study UK Japan Joint Study for Risk Factors of Lymph Node Metastasis in Submucosal Invasive (pt1) Colorectal Cancer Assessment criteria of pathological parameters
More informationBC CRC Update Malignant Polyp Who Needs Surgery
BC CRC Update Malignant Polyp Who Needs Surgery Anthony MacLean, MD, FRCSC, FACS, FASCRS Colorectal Surgeon Foothills Medical Centre Clinical Associate Professor of Surgery and Oncology University of Calgary
More informationPrinciples of diagnosis, work-up and therapy The Gastroenterologist s role
Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationShort and longterm outcomes after endoscopic resection of malignant polyps.
Short and longterm outcomes after endoscopic resection of malignant polyps. Short and longterm outcomes High risk features Lymph node metastasis Lymph node metastases sm1 sm2 sm3 Son 2008 3.1 % 14.9% 25.0
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationQuality Measures In Colonoscopy: Why Should I Care?
Quality Measures In Colonoscopy: Why Should I Care? David Greenwald, MD, FASGE Professor of Clinical Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York ACG/ASGE Best
More informationUpdate on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017
Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationScreening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee
Screening for GI Cancer Past Present and Future Prof. Bob Steele University of Dundee Worldwide Cancer Incidence Rates UK Cancer Incidence Rates Screening The detection of disease in asymptomatic subjects
More informationQuality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationBowel Screening Colonoscopy in Glasgow How well are we doing? How well should we be doing? How can we evidence and improve performance?
Bowel Screening Colonoscopy in Glasgow 2017 How well are we doing? How well should we be doing? How can we evidence and improve performance? Bowel Screening Standards - Scotland Definitions Completion
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationEXPERT WORKING GROUP Surveillance after neoplasia removal. Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum
EXPERT WORKING GROUP Surveillance after neoplasia removal Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum AIM To improve the quality of the evidences we have regarding post- polypectomy
More information